Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms

Abstract

Halogenated aliphatic carboxylic acids, salts and/or oligomers or polymers thereof, which exhibit a devitalizing effect of neoplastic tissues, are disclosed. Methods and uses that utilize these compounds for the treatment of medical conditions associated with a neoplastic tissue are also disclosed. Further disclosed are methods and uses that utilize these compounds for reducing or abolishing blood and lymph as well local dissemination of malignant neoplastic cells during a surgical removal thereof, thereby preventing recurrences and distance metastases, and/or inducing immune response to potentially malignant, pre-malignant and/or malignant cells. Further disclosed are novel oligomeric forms of halogenated aliphatic carboxylic acids, pharmaceutical compositions containing same and uses thereof.

What is claimed is: 
     
         1 . A method of treating a medical condition associated with neoplastic tissue in a subject in need thereof, the method comprising administering to the subject a devitalizing effective amount of a compound which is 2,2-dichloropropanoic acid or a pharmaceutical acceptable salt thereof, by locally administering the compound onto and/or into said neoplastic tissue,
 wherein said salt does not comprise selenium.   
     
     
         2 . The method of  claim 1 , wherein said compound forms a part of a pharmaceutical composition which further comprises a pharmaceutically acceptable carrier. 
     
     
         3 . The method of  claim 2 , wherein a concentration of said compound in said composition ranges from 70 weight percents to 90 weight percents of the total weight of said composition. 
     
     
         4 . The method of  claim 2 , wherein a devitalizing effective amount of said compound ranges from 0.001 ml to 5 ml of said composition per a neoplastic tissue diameter of 1 cm. 
     
     
         5 . The method of  claim 1 , further comprising surgically removing at least a portion of said neoplastic tissue. 
     
     
         6 . The method of  claim 1 , wherein said disorder is associated with malignant neoplastic tissue, the method being for reducing or abolishing dissemination of malignant cells into blood or lymph vessels. 
     
     
         7 . The method of  claim 1 , wherein said neoplastic tissue is selected from the group consisting of a skin or mucosal tissue and an internal tissue. 
     
     
         8 . The method of  claim 1 , wherein said neoplastic tissue is a solid malignant tumor. 
     
     
         9 . A method of reducing or abolishing dissemination of malignant cells into a blood and/or lymph vessel of a subject having a medical condition associated with malignant neoplastic tissue and subjected to a surgical procedure for removing at least a portion of said malignant neoplastic tissue, the method comprising administering to the subject, prior to, concomitant with or subsequent to the surgical procedure, a devitalizing effective amount of a compound which is 2,2-dichloropropanoic acid or a pharmaceutical acceptable salt thereof, by locally administering the compound onto and/or into said neoplastic tissue,
 wherein said salt does not comprise selenium.   
     
     
         10 . The method of  claim 9 , wherein a devitalizing effective amount of said compound ranges from 0.001 ml to 5 ml of said composition per a neoplastic tissue diameter of 1 cm. 
     
     
         11 . The method of  claim 9 , wherein said neoplastic tissue is skin or mucosal tissue. 
     
     
         12 . The method of  claim 11 , wherein said medical condition is a metastasizing malignant skin or mucosal tumor. 
     
     
         13 . The method of  claim 11 , wherein said medical condition is a malignant solid tumor. 
     
     
         14 . The method of  claim 11  wherein said administering is effected topically. 
     
     
         15 . The method of  claim 9 , wherein said neoplastic tissue is an internal tissue. 
     
     
         16 . The method of  claim 15 , wherein said administering is effected intracorporeally. 
     
     
         17 . The method of  claim 15 , wherein said administering is performed during a surgical procedure. 
     
     
         18 . A method of treating a medical condition associated with neoplastic tissue in a subject in need thereof, the method comprising administering to the subject a devitalizing effective amount of a compound which is 2,2-dichloropropanoic acid or a pharmaceutical acceptable salt or complex thereof, said administering being performed by locally administering the compound onto and/or into said neoplastic tissue during a surgical procedure for removing at least a portion of said neoplastic tissue. 
     
     
         19 . The method of  claim 18 , wherein said compound forms a part of a pharmaceutical composition which further comprises a pharmaceutically acceptable carrier. 
     
     
         20 . The method of  claim 19 , wherein a concentration of said compound in said composition ranges from 70 weight percents to 90 weight percents of the total weight of said composition. 
     
     
         21 . The method of  claim 19 , wherein a devitalizing effective amount of said compound ranges from 0.001 ml to 5 ml of said composition per a neoplastic tissue diameter of 1 cm. 
     
     
         22 . The method of  claim 18 , wherein said disorder is associated with malignant neoplastic tissue, the method being for reducing or abolishing dissemination of malignant cells into blood or lymph vessels. 
     
     
         23 . The method of  claim 18 , wherein said neoplastic tissue is selected from the group consisting of a skin or mucosal tissue and an internal tissue. 
     
     
         24 . The method of  claim 18 , wherein said neoplastic tissue is a solid malignant tumor. 
     
     
         25 . A method of reducing or abolishing dissemination of malignant cells into a blood and/or lymph vessel of a subject having a medical condition associated with malignant neoplastic tissue and subjected to a surgical procedure for removing at least a portion of said malignant neoplastic tissue, the method comprising administering to the subject, prior to, concomitant with or subsequent to the surgical procedure, a devitalizing effective amount of a compound which is 2,2-dichloropropanoic acid or a pharmaceutical acceptable salt thereof,
 wherein said administering is performed by locally administering the compound onto and/or into said neoplastic tissue during the surgical procedure.   
     
     
         26 . The method of  claim 25 , wherein a devitalizing effective amount of said compound ranges from 0.001 ml to 5 ml of said composition per a neoplastic tissue diameter of 1 cm. 
     
     
         27 . The method of  claim 25 , wherein said neoplastic tissue is skin or mucosal tissue. 
     
     
         28 . The method of  claim 27 , wherein said medical condition is a metastasizing malignant skin or mucosal tumor. 
     
     
         29 . The method of  claim 27 , wherein said medical condition is a malignant solid tumor. 
     
     
         30 . The method of  claim 27  wherein said administering is effected topically. 
     
     
         31 . The method of  claim 25 , wherein said neoplastic tissue is an internal tissue. 
     
     
         32 . The method of  claim 31 , wherein said administering is effected intracorporeally.